Please login to the form below

Not currently logged in
Email:
Password:

Bridion

This page shows the latest Bridion news and features for those working in and with pharma, biotech and healthcare.

FDA approvals hit 19-year high

FDA approvals hit 19-year high

Among these, the FDA highlighting Merck &Co's neuromuscular blockade reversal agent Bridion (sugammadex), Pfizer's CD4/6 inhibitor Ibrance (palbociclib) for breast cancer and Boehringer Ingelheim's Praxbind (idarucizumab), a

Latest news

  • Merck finally bags FDA approval for Bridion Merck finally bags FDA approval for Bridion

    Merck finally bags FDA approval for Bridion. Follows three unsuccessful attempts to gain a US licence for the drug. ... Merck said it plans to launch Bridion in January and will announce Bridion's price at that time.

  • At long last, Merck gets FDA panel backing for Bridion At long last, Merck gets FDA panel backing for Bridion

    After several knockbacks, Merck &Co has finally moved a key step closer to securing FDA approval for its muscle relaxant reversal agent Bridion. ... Bridion (sugammadex) was first rejected by the FDA in 2008, and was turned down once again in 2013.

  • Merck faces another Bridion knockback Merck faces another Bridion knockback

    Merck faces another Bridion knockback. It is seven years since the FDA initially rejected it. ... Bridion was acquired by Merck when it took over Schering-Plough in 2009.

  • R&D in the firing line as Merck & Co axes 8,500 jobs R&D in the firing line as Merck & Co axes 8,500 jobs

    Recent setbacks in Merck's late-stage pipeline include a delay in US approval of anaesthesia drug Bridion (sugammadex) and an FDA rejection for insomnia candidate suvorexant, while the company has

  • FDA rejects Merck muscle relaxant drug once again FDA rejects Merck muscle relaxant drug once again

    FDA rejects Merck muscle relaxant drug once again. Regulator still has hypersensitivity concerns about Bridion. ... reactions that was requested by the FDA when it turned Bridion down for the first time in 2008.

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics